Free Trial

Protagonist Therapeutics (PTGX) Competitors

Protagonist Therapeutics logo
$124.23 -6.72 (-5.13%)
Closing price 03:59 PM Eastern
Extended Trading
$124.50 +0.27 (+0.22%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PTGX vs. GMAB, ROIV, INSM, UTHR, and INCY

Should you buy Protagonist Therapeutics stock or one of its competitors? Protagonist Therapeutics's main competitors and comparable companies include Genmab A/S (GMAB), Roivant Sciences (ROIV), Insmed (INSM), United Therapeutics (UTHR), and Incyte (INCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Protagonist Therapeutics compare to Genmab A/S?

Protagonist Therapeutics (NASDAQ:PTGX) and Genmab A/S (NASDAQ:GMAB) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by insiders. Comparatively, 1.5% of Genmab A/S shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Protagonist Therapeutics presently has a consensus price target of $166.67, suggesting a potential upside of 27.28%. Genmab A/S has a consensus price target of $53.50, suggesting a potential upside of 4.15%. Given Protagonist Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Protagonist Therapeutics is more favorable than Genmab A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Protagonist Therapeutics
0 Sell rating(s)
0 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
3.06
Genmab A/S
0 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
3.00

Genmab A/S has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protagonist Therapeutics$46.02M185.73-$130.15M$4.7227.74
Genmab A/S$3.72B8.62$963M$1.1743.91

Protagonist Therapeutics has a net margin of 62.04% compared to Genmab A/S's net margin of 16.97%. Protagonist Therapeutics' return on equity of 42.83% beat Genmab A/S's return on equity.

Company Net Margins Return on Equity Return on Assets
Protagonist Therapeutics62.04% 42.83% 40.29%
Genmab A/S 16.97%13.67%6.42%

Protagonist Therapeutics has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market.

In the previous week, Protagonist Therapeutics and Protagonist Therapeutics both had 19 articles in the media. Protagonist Therapeutics' average media sentiment score of 0.97 beat Genmab A/S's score of -0.15 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Protagonist Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Genmab A/S
3 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Protagonist Therapeutics beats Genmab A/S on 12 of the 15 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Roivant Sciences?

Protagonist Therapeutics (NASDAQ:PTGX) and Roivant Sciences (NASDAQ:ROIV) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

Protagonist Therapeutics presently has a consensus price target of $166.67, indicating a potential upside of 27.28%. Roivant Sciences has a consensus price target of $46.64, indicating a potential upside of 17.98%. Given Protagonist Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Protagonist Therapeutics is more favorable than Roivant Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Protagonist Therapeutics
0 Sell rating(s)
0 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
3.06
Roivant Sciences
1 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.79

Protagonist Therapeutics has a net margin of 62.04% compared to Roivant Sciences' net margin of -838.21%. Protagonist Therapeutics' return on equity of 42.83% beat Roivant Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Protagonist Therapeutics62.04% 42.83% 40.29%
Roivant Sciences -838.21%-22.03%-20.55%

98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 8.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Protagonist Therapeutics has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protagonist Therapeutics$46.02M185.73-$130.15M$4.7227.74
Roivant Sciences$8.26M3,467.54-$299.77M-$0.63N/A

In the previous week, Roivant Sciences had 8 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 27 mentions for Roivant Sciences and 19 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.97 beat Roivant Sciences' score of 0.50 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Protagonist Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Roivant Sciences
7 Very Positive mention(s)
3 Positive mention(s)
11 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Protagonist Therapeutics has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market.

Summary

Protagonist Therapeutics beats Roivant Sciences on 12 of the 16 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Insmed?

Protagonist Therapeutics (NASDAQ:PTGX) and Insmed (NASDAQ:INSM) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

Protagonist Therapeutics currently has a consensus target price of $166.67, indicating a potential upside of 27.28%. Insmed has a consensus target price of $196.52, indicating a potential upside of 62.20%. Given Insmed's higher probable upside, analysts clearly believe Insmed is more favorable than Protagonist Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Protagonist Therapeutics
0 Sell rating(s)
0 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
3.06
Insmed
1 Sell rating(s)
1 Hold rating(s)
23 Buy rating(s)
1 Strong Buy rating(s)
2.92

Protagonist Therapeutics has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market. Comparatively, Insmed has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

Protagonist Therapeutics has a net margin of 62.04% compared to Insmed's net margin of -39.85%. Protagonist Therapeutics' return on equity of 42.83% beat Insmed's return on equity.

Company Net Margins Return on Equity Return on Assets
Protagonist Therapeutics62.04% 42.83% 40.29%
Insmed -39.85%-96.38%-32.55%

98.6% of Protagonist Therapeutics shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by insiders. Comparatively, 2.1% of Insmed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Protagonist Therapeutics had 11 more articles in the media than Insmed. MarketBeat recorded 19 mentions for Protagonist Therapeutics and 8 mentions for Insmed. Insmed's average media sentiment score of 1.17 beat Protagonist Therapeutics' score of 0.97 indicating that Insmed is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Protagonist Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Insmed
5 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Protagonist Therapeutics has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protagonist Therapeutics$46.02M185.73-$130.15M$4.7227.74
Insmed$606.42M43.83-$1.28B-$2.82N/A

Summary

Protagonist Therapeutics beats Insmed on 12 of the 16 factors compared between the two stocks.

How does Protagonist Therapeutics compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Protagonist Therapeutics (NASDAQ:PTGX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

Protagonist Therapeutics has a net margin of 62.04% compared to United Therapeutics' net margin of 38.61%. Protagonist Therapeutics' return on equity of 42.83% beat United Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
United Therapeutics38.61% 19.18% 17.07%
Protagonist Therapeutics 62.04%42.83%40.29%

United Therapeutics has higher revenue and earnings than Protagonist Therapeutics. United Therapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
United Therapeutics$3.18B7.91$1.33B$26.5022.31
Protagonist Therapeutics$46.02M185.73-$130.15M$4.7227.74

In the previous week, United Therapeutics had 10 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 29 mentions for United Therapeutics and 19 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.97 beat United Therapeutics' score of 0.96 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
United Therapeutics
13 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Protagonist Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

United Therapeutics has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market.

United Therapeutics currently has a consensus price target of $676.40, indicating a potential upside of 14.42%. Protagonist Therapeutics has a consensus price target of $166.67, indicating a potential upside of 27.28%. Given Protagonist Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Protagonist Therapeutics is more favorable than United Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
United Therapeutics
1 Sell rating(s)
3 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.69
Protagonist Therapeutics
0 Sell rating(s)
0 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
3.06

Summary

Protagonist Therapeutics beats United Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Incyte?

Incyte (NASDAQ:INCY) and Protagonist Therapeutics (NASDAQ:PTGX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

97.0% of Incyte shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 16.2% of Incyte shares are owned by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Incyte currently has a consensus price target of $132.86, indicating a potential upside of 9.83%. Protagonist Therapeutics has a consensus price target of $166.67, indicating a potential upside of 27.28%. Given Protagonist Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protagonist Therapeutics is more favorable than Incyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Incyte
0 Sell rating(s)
14 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.44
Protagonist Therapeutics
0 Sell rating(s)
0 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
3.06

Protagonist Therapeutics has a net margin of 62.04% compared to Incyte's net margin of 6.71%. Protagonist Therapeutics' return on equity of 42.83% beat Incyte's return on equity.

Company Net Margins Return on Equity Return on Assets
Incyte6.71% 7.92% 6.12%
Protagonist Therapeutics 62.04%42.83%40.29%

Incyte has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Incyte$6.01B4.10$1.29B$1.8864.35
Protagonist Therapeutics$46.02M185.73-$130.15M$4.7227.74

Incyte has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market.

In the previous week, Protagonist Therapeutics had 1 more articles in the media than Incyte. MarketBeat recorded 19 mentions for Protagonist Therapeutics and 18 mentions for Incyte. Protagonist Therapeutics' average media sentiment score of 0.97 beat Incyte's score of 0.45 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Incyte
8 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
3 Very Negative mention(s)
Neutral
Protagonist Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Protagonist Therapeutics beats Incyte on 13 of the 17 factors compared between the two stocks.

Get Protagonist Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PTGX vs. The Competition

MetricProtagonist TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$8.11B$4.06B$7.83B$11.76B
Dividend YieldN/A3.64%2.47%4.41%
P/E Ratio26.3224.2134.3230.12
Price / Sales176.1914.858.005.33
Price / CashN/A21.8921.0222.32
Price / Book12.644.354.763.85
Net Income-$130.15M-$24.19M$3.52B$391.27M
7 Day Performance-8.59%-7.23%-5.35%-4.55%
1 Month Performance-3.51%-4.94%-3.62%-5.89%
1 Year Performance46.82%-4.60%-0.62%-7.84%

Protagonist Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PTGX
Protagonist Therapeutics
3.5254 of 5 stars
$124.23
-5.1%
$166.67
+34.2%
+54.8%$8.11B$46.02M26.32141
GMAB
Genmab A/S
2.2278 of 5 stars
$51.37
-0.7%
$53.50
+4.1%
+69.8%$32.29B$3.72B39.803,029
ROIV
Roivant Sciences
2.2333 of 5 stars
$39.53
-1.2%
$46.64
+18.0%
+94.8%$28.89B$8.26MN/A721
INSM
Insmed
3.3417 of 5 stars
$121.16
+2.6%
$196.52
+62.2%
-37.3%$25.90B$606.42MN/A1,664
UTHR
United Therapeutics
4.7069 of 5 stars
$591.17
-0.4%
$676.40
+14.4%
+26.8%$25.27B$3.19B22.311,400

Related Companies and Tools


This page (NASDAQ:PTGX) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners